NCT05904626 - Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions

Intestinal Malabsorption

Interventions

DRUG

ELGN-2112

To compare the safety of treatment with ELGN-2112 to placebo in preterm infants born less than 26 weeks GA and IUGR infants\<3rd percentile\* born at 26-32 weeks GA.

DRUG

Placebo

A placebo formulation consisting of the same inactive ingredients as ELGN-2112.